Home » Newsletters » BioWorld Science

BioWorld Science

July 16, 2012

View Archived Issues

Researchers at Lycera prepare new F1F0 ATPase inhibitors

Bristol-Myers Squibb patents new agents for HIV infection

Japanese team discloses novel treatments for diabetes

New EFNA modulators designed by Stem CentRx

New fusion protein from Bristol-Myers Squibb demonstrates antidiabetic activity

Bracco designs novel vaccines for allergy

New D3/5-HT2A receptor modulators patented by Roche

Belgian group discloses novel treatments for neurodegenerative disorders

NPS-1034 shows promise in EGFR-mutant cancer models

Grifols invests in biotechnology firm

CHF-5074 is well tolerated in patients with mild cognitive impairment

GlobeImmune patents novel vaccines for Ad-36 infection and obesity

Alnylam and Ascletis enter collaboration

GlaxoSmithKline withdraws supplemental NDA for Tykerb

Intranasal CP-024 leads to IGF-I induction in healthy volunteers

SEMA7A may have potential as a therapeutic target in breast cancer

Neupro launched in U.S. for Parkinson's disease and RLS

GSK and Theravance file applications for combination COPD candidate

Topline results expected early from phase IIb study of vigabatrin

Tissue Therapies obtains CE Mark for VitroGro ECM wound care product

OncoGenex provides update on phase III development of anticancer candidate

Supernus clarifies tentative approval conditions for Trokendi XR

In vivo results for ARRY-981 presented

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...